Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones(The Ohio State University), John C. Byrd(University of Cincinnati), Richard R. Furman(Cornell University), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lang Zhou(Qingdao University), Steven Coutré(Georgetown University), Ahmed Hamed Salem(Ain Shams University), Paul M. Barr(University of Rochester Medical Center), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Brenda Chyla(AbbVie (United States)), Michael Y. Choi(University of California San Diego), Bruce D. Cheson(Center for Cancer and Blood Disorders), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Anthony R. Mato(University of Pennsylvania), Maria Verdugo(AbbVie (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 378
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k